3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
5
Recurrence
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms, Basal Cell
1
Keratosis, Actinic
1
Colorectal Neoplasms
1
Carcinoma, Basal Cell
1
Interventions
Gemcitabine
15
Mitomycin
10
Docetaxel
7
BCG Vaccine
7
Cystoscopy
4
tislelizumab
3
durvalumab
3
Radiotherapy
3
Epirubicin
3
disitamab vedotin
2
avelumab
2
Hyaluronic Acid
2
tremelimumab
1
toripalimab
1
pemigatinib
1
pembrolizumab
1
monalizumab
1
lornoxicam
1
erdafitinib
1
enzalutamide
1
chondroitin sulfate, sodium hyaluronate drug combination
1
bicalutamide
1
Watchful Waiting
1
VPM1002 recombinant BCG vaccine
1
Urine Specimen Collection
1
Ty21a typhoid vaccine
1
Transurethral Resection of Bladder
1
Therapeutics
1
Surveys and Questionnaires
1
Sugars
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Non-Muscle Invasive Bladder Neoplasms
×
5-aminolevulinic acid hexyl ester
×
Clear all
NCT05962541
2025-12-31
CUT-less
University of Roma La Sapienza
Phase 4
Recruiting
327 enrolled